Total orthotopic heart transplantation for primary cardiac rhabdomyosarcoma: Factors influencing long-term survival

被引:20
作者
Grandmougin, D
Fayad, G
Decoene, C
Pol, A
Warembourg, H
机构
[1] Hop Cardiol, Dept Cardiovasc Surg, Serv Chirurg Cardiovasc, F-59037 Lille, France
[2] Univ Lille, Calmette Hosp, Dept Pathol, Lille, France
关键词
D O I
10.1016/S0003-4975(01)02480-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Primary cardiac sarcomas are uncommon and rare, with an unequal distribution in the population. A dismal prognosis is usually admitted that is related to a high propensity to develop distant metastasis with survival rarely exceeding 2 years. We report a case of a patient with a primary cardiac rhabdomyosarcoma characterized by an exceptional long-term survival after surgical treatment by a total orthotopic heart transplantation From this limited experience, we reviewed factors that may influence survival to optimize therapeutic strategy. Methods. A 33-year-old man was found to have a 10-cm primary cardiac rhabdomyosarcoma located in the right atrium and extending to the atrioventricular groove; therefore, resection was not possible. Since no metastases were detected, the patient was scheduled for urgent cardiac transplantation, which was performed after adjuvant radiotherapy. Results. Postoperative outcome was uneventful and the patient is still alive, with regular follow-up, at 102 months. Conclusions. In a case of primary rhabdomyosarcoma, heart transplantation, despite immunosuppressive therapy, can provide long-term survival and can be considered for selected patients after rigorous analysis of predictors of survival. (Ann Thorac Surg 2001;71:1438-41) (C) 2001 by The Society of Thoracic Surgeons.
引用
收藏
页码:1438 / 1441
页数:4
相关论文
共 18 条
[1]  
Aravot D J, 1989, Eur J Cardiothorac Surg, V3, P521, DOI 10.1016/1010-7940(89)90112-7
[2]  
Blondeau P, 1990, Thorac Cardiovasc Surg, V38 Suppl 2, P192, DOI 10.1055/s-2007-1014065
[3]  
BURKE AP, 1995, ATLAS TUMOR PATHOL, P157
[4]  
COLOMBUS MR, 1562, ANATOMICA
[5]  
CRESPO MG, 1993, J HEART LUNG TRANSPL, V12, P527
[6]   RANDOMIZED COMPARISON OF DOXORUBICIN ALONE VERSUS IFOSFAMIDE PLUS DOXORUBICIN OR MITOMYCIN, DOXORUBICIN, AND CISPLATIN AGAINST ADVANCED SOFT-TISSUE SARCOMAS [J].
EDMONSON, JH ;
RYAN, LM ;
BLUM, RH ;
BROOKS, JSJ ;
SHIRAKI, M ;
FRYTAK, S ;
PARKINSON, DR .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1269-1275
[7]  
GASUL BM, 1996, HEART DIS CHILDREN, P1086
[8]  
HASHIMOTO H, 1992, CANCER-AM CANCER SOC, V70, P2816, DOI 10.1002/1097-0142(19921215)70:12<2816::AID-CNCR2820701215>3.0.CO
[9]  
2-4
[10]  
Hui K S, 1988, Am J Cardiovasc Pathol, V2, P19